Eli Lilly announced the results of Phase 3 clinical trials of orforglipron for type 2 diabetes in adult patients[1]. The ACHIEVE-1 study lasted 40 weeks and compared the effects of the drug with a placebo[1]. More than 65% of volunteers taking the highest dose achieved A1C targets[1]. The drug has shown a significant reduction in blood sugar and weight[1][3]. In clinical trials, orforglipron achieved a 12.4% reduction in body weight[3]. The study met expectations for safety, tolerability, glucose control and weight loss[1]. The results will be presented at the 85th annual conference of the American Diabetes Association and published in a peer-reviewed scientific publication[1]. More data from this and other studies will be published later[1].